Trulicity [Prescribing Information]. Francesco Giorgino Send a message. 2020 Feb;80(2):197-208. doi: 10.1007/s40265-020-01260-9. © 2020 MJH Life Sciences and HCPLive. Diabetes Ther. 0 views XX downloads; XX citations; Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials. Open in new tab . 2018. Prof. Francesco Giorgino Bari, 2 febbraio 2008 Vecchi e Nuovi Farmaci nel Trattamento del Diabete Tipo 2 Dipartimento dell’Emergenza e dei Trapianti di Organi Sezione di Medicina Interna, Endocrinologia e Malattie Metaboliche Università degli Studi di Bari 1°Congresso Regionale SIMG Puglia Il Farmaco come Risorsa per la Salute. Visualizza il profilo di Francesco Giorgino su LinkedIn, la più grande comunità professionale al mondo. Changes in glycaemic measures in response to treatment with dulaglutide or glargine were evaluated in each subgroup. Drugs. Diabetes mellitus is a chronic common metabolic disorder . Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Metformin should remain as ‘foundation therapy’ for the majority of patients with T2D: Yes (Francesco Giorgino) or No (Nikolaus Marx) Silvio Inzucchi and Francesco Giorgino. Francesco Giorgino Show Co-Speakers Efficacy and safety of once weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) Francesco Giorgino; International Journal of Obesity. 2015 Dec;38(12):2241-9. doi: 10.2337/dc14-1625. 2016 Nov;128(8):810-821. doi: 10.1080/00325481.2016.1218260. © 2019 The Authors. In 2016, more than 3.2 million people in Italy were reported to suffer from diabetes, representing 5.3% of the total population (16.5% among people aged 65 and over) . Schematic representation of the major signaling pathways through which GLP-1 activates multiple biological responses in β- cells. Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F. Diabetes Obes Metab. This site needs JavaScript to work properly. GLP-1; basal insulin; dulaglutide; type 2 diabetes. Diabetes Care. The GLP-1RA could also inhibit the further reduce the development of arthrosclerosis and the incidence of stroke and cardiovascular events in type 2 diabetes. Diapositiva preparata da FRANCESCO GIORGINO e ceduta alla Società Italiana di Diabetologia. Dulaglutide: A Review in Type 2 Diabetes. Epub 2017 Apr 10. Welcome and introduction. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). He also said the individual circumstances are important when considering which treatment option to go with, including whether the patient is obese or whether they are already featuring a decrease in renal function. The long-acting glucagon-like peptide-1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose-dependent manner both in the fasting and postprandial states, resulting in reductions of both fasting glucose (FG) and postprandial glucose (PPG). L'intervista del professor Francesco Giorgino, del dipartimento di Endocrinologia dell’Università di Bari, ai microfoni di Controradio. Contribution to sentiment. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. F.G. serves or has served on the advisory boards for AstraZeneca, Eli Lilly and Company, Roche Diabetes Care, and NovoNordisk, serves or has served as a consultant for AstraZeneca, Boehringer‐Ingelheim, Lifescan, Merck Sharp & Dohme and Sanofi, and has received research support from AstraZeneca, Eli Lilly and Company, Lifescan and Takeda. Department of Emergency and Organ Transplantation Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy View ORCID profile See all articles by this author. A major breakthrough in diabetes treatment in the last few years has been the advent of SGLT2 inhibitors as a medication that also assists in helping with kidney function, while lowering the risk of cardiovascular events. Francesco Giorgino and Nikolaus Marx. Epub 2015 Jun 18. Epub 2017 Sep 14. Studi sugli animali Email: francesco.giorgino@uniba.it. Data presented as least squares mean (95% CI); intention‐to‐treat population, without post‐rescue visits. Partial data from this study have been previously presented at the American Diabetes Association 78th Annual Scientific Sessions, held in Orlando, Florida, June 22–26, 2018, and at the 54th Annual Meeting of the European Association for the Study of Diabetes, held in Berlin, Germany, October 1–5, 2018. Eli Lilly and Company. The aim of the present post hoc analysis of the phase 3 AWARD-2 trial was to investigate whether specific baseline glycaemic patterns respond differentially to dulaglutide compared to insulin glargine (glargine). 1. Change from baseline in glycaemic measures and body weight at 52 weeks by…, NLM 2003;46(Suppl 1):M9‐M16. Thus far, SGLT2 inhibitors have shown efficacy in reducing hospitalizations for heart failure and effect positively the decline in renal function in type 2 diabetes. Basal insulin therapy in type 2 diabetes: 28‐week comparison of insulin glargine (HOE 901) and NPH insulin. Angelo Cignarelli, MD, PhD 1. Francesco Giorgino; Non categorizzato. View Abstract . USA.gov. Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z. Diabetes Obes Metab. Epub 2020 Jun 20. Download. Francesco Giorgino As seen in: Color Research & Application ... .com — Abstract Approximately 50% of patients with type 2 diabetes mellitus (T2DM) do not achieve glycemic targets and require treatment intensification. Giorgino / Diabetes Research and Clinical Practice 74 (2006) S152–S155 S153 Fig. Francesco Giorgino, Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Piazza Giulio Cesare, 11, 70124 Bari, Italy. 451 views . © 2020 MJH Life Sciences™ and HCPLive. The relationship between glucose control and cardiovascular outcomes in type 2 diabetes has been a matter of controversy over the years. M.Y., Z.M., A.H. and L.E.G.P. L’autore Francesco Giorgino dichiara di aver ricevuto compensi per collaborazione scientifica da Abbott, Roche Diabetes Care, Lifescan. All rights reserved. See this image and copyright information in PMC. Epub 2016 Aug 12. Authors Francesco Giorgino 1 , Marian Benroubi 2 , Jui-Hung Sun 3 , Alan G Zimmermann 4 , Valeria Pechtner 5 Affiliations 1 University of Bari Aldo Moro, Bari, Italy. 2017 Jul;19(7):1024-1031. doi: 10.1111/dom.12937. https://www.hcplive.com/view/giorgino-diabetes-treatment-sglt2-inhibitors Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. View Abstract. Consistently, in 2018, the diabetes tweets mostly expressed emotions of trust, fear, and anticipation, whereas in 2020, fear was the most represented emotion, followed by sadness . Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it Il Prof Francesco Giorgino dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle … Lisbon 2017. Professor Giorgino’s research interests include the mechanisms leading to insulin resistance and beta-cell dysfunction in Type 2 diabetes with a particular focus on skeletal muscle metabolism and organ cross-talk, inflammation and lipotoxicity, and the effects of diabetes drugs on pancreatic islets and the cardiovascular system. 29 Settembre 2020. 2017 Dec 28;64(12):1165-1172. doi: 10.1507/endocrj.EJ17-0189. -, Riddle MC. Arch Intern Med. Silvio Inzucchi and Sarah Jarvis. Clinical significance, pathogenesis, and management of postprandial hyperglycaemia. Epub 2017 Feb 17. Basal glucose can be controlled, but the prandial problem persists‐It's the next target! Angelo Cignarelli . 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. L’autore Giuseppe Lisco dichiara di non avere conflitti di interesse. Francesco Giorgino, Università di Bari, IBDO Foundation Gerardo Medea, SIMG, IBDO Foundation Paolo Sbraccia, Università di Roma "Tor Vergata", IBDO Foundation Federico Spandonaro, Università Roma "Tor Vergata", IBDO Foundation Ketty Vaccaro, Fondazione CENSIS, IBDO Foundation. http://pi.lilly.com/us/trulicity-uspi.pdf, Gerich J. Email: francesco.giorgino@uniba.it KEYWORDS:COVID-19, diabetes, lung, SARS-CoV-2 The SARS-CoV-2 infection is spreading fast and represents a menac-ing threat to global health. Francesco Giorgino, Marian Benroubi, Jui-Hung Sun, Alan G. Zimmermann, Valeria Pechtner Diabetes Care Dec 2015, 38 (12) 2241-2249; DOI: 10.2337/dc14-1625 Share This Article: Copy Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetologia. Francesco Giorgino, University of Bari Aldo Moro, Piazza Giulio Cesare, n. 11, Bari, 70124, Italy. Diabetes Care. The possible role of post‐prandial hyperglycaemia in the pathogenesis of diabetic complications. Generation of cyclic AMP (cAMP) and activation of protein kinase A (PKA) and Epac proteins appear to be involved in stim- ulation of insulin secretion by GLP-1. Search for more papers by this author. his artworks are characterized by child like figures, simple monochromatic lines combined with a dash of color, and elements of architecture. Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. 2003;163:1306‐1316. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error, Change from baseline in glycaemic measures and body weight at 52 weeks by subgroups in people treated with dulaglutide 1.5 mg or insulin glargine. Search for more papers by this … Greater HbA1c reductions were observed with dulaglutide 1.5 mg compared to glargine in all subgroups (all P ≤ .05), except in the low FG/high PPG subgroup. Figure 1. 2020 Aug;11(8):1627-1638. doi: 10.1007/s13300-020-00863-5. Francesco Giorgino Scritto da il 27 Settembre 2020 To assess perceptions related to erectile dysfunction (ED) and premature eja...The latest recommendations from the American Diabetes Association and the European Association for the Study of Diabetes prioritize the use of drugs with proven cardiovascular (CV) benefit in patients with established CV disease. In contrast, the main mechanism of action of basal insulin is to reduce elevated FG by inhibiting hepatic glucose production. Clipboard, Search History, and several other advanced features are temporarily unavailable. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.  |  Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice? Peter Fenici MD. francesco giorgino, ravi retnakaran, josep vidal, vanita aroda, aramesh saremi, minzhi liu Diabetes Jul 2018, 67 (Supplement 1) 1095-P; DOI: 10.2337/db18-1095-P Share This Article: Copy Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) Diabetes Care. 2017;40(3):291‐300. Kaneko S, Oura T, Matsui A, Shingaki T, Takeuchi M. Endocr J. The … -, Ceriello A. are employees and shareholders of Eli Lilly and Company. Diapositiva preparata da FRANCESCO GIORGINO e ceduta alla Società Italiana di Diabetologia. Francesco Giorgino, MD, 1 Alka Shaunik, MD, 2 Minzhi Liu, PhD, 2 and Aramesh Saremi, MD 2 Author ... Diabetes is associated with accelerated risk of atherosclerosis. Cross-specialty debates in diabetes. Le importanti dichiarazione del prof. Francesco Giorgino, prestigioso accademico specialista medico, che da anni si occupa di obesità, diabete mellito e … By Kamlesh Khunti, Francesco Giorgino, Lori Berard, Dídac Mauricio dom-pubs.onlinelibrary.wiley.com — Abstract Achieving target glycaemic control is essential in people with diabetes to minimize the risk of long‐term complications, and many people with type 2 diabetes will ultimately require basal insulin (BI) therapy to achieve their individualized glycaemic targets. All rights reserved. Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.  |  Published on 01 Feb 2020. Anderson JE, Thieu VT, Boye KS, Hietpas RT, Garcia-Perez LE. Epub 2017 Oct 5. NIH At 52 weeks, significant reductions from baseline in glycated haemoglobin (HbA1c) were observed in all subgroups with dulaglutide 1.5 mg and with glargine (all P < .05), except in patients with low FG/low PPG who received glargine. -. 1.UNA PANDEMIA CHE AVANZA. Diabetes Obes Metab. During the 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference presented by the Metabolic Institute of America (TMIOA), Francesco Giorgino, MD, PhD, professor of Endocrinology and Metabolism, chief of the Division of Endocrinology, and Director of the Specialty School of Endocrinology and Metabolism at the University Hospital Policlinico Consorziale, University of Bari Aldo Moro, presented new information about using SGLT2 inhibitors, GLP-1RA, or an initial combination of both as treatment for type 2 diabetes. Please enable it to take advantage of the complete set of features! -, Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. gennaio 11, 2016 Supplemental Figure 2: Correlation analysis between uAQP5 and uACR or CKD-EPI. Overall, Giorgino suggests both treatments could be combined for the benefit of many patients. 2001;24(4):631‐636. HHS Francesco Giorgino . Giorgino explained in an interview with HCPLive®, how these medications have shaped treatment plans for patients with type 2 diabetes. View ePoster. Search for more papers by this author. Guarda il profilo completo su LinkedIn e scopri i collegamenti di Francesco e le offerte di lavoro presso aziende simili. The long-acting glucagon-like peptide-1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose-dependent manner both in the fasting and postprandial states, resulting in reductions of both fasting glucose (FG) and postprandial glucose (PPG). *. We categorized participants into four subgroups based on prespecified glucose thresholds and their baseline FG and daily 2-hour mean PPG: low FG/low PPG; low FG/high PPG; high FG/low PPG; and high FG/high PPG. Department of Diabetes and Endocrinology, University of Liverpool, Liverpool, UK . COVID-19 is an emerging, rapidly evolving situation. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Download in PowerPoint. 2018 Feb;20(2):409-418. doi: 10.1111/dom.13086.  |  In 2014, the global prevalence of diabetes was estimated to be 9% among adults aged more than 18 years . Consenso informato. AstraZeneca, Cambridge, UK. Keywords: Postgrad Med. Per ricevere la versione originale si prega di scrivere a siditalia@siditalia.it GLUT1/2, glucose transporter 1/2; SGLT1/2, sodium –glucose co -transporter 1/2 1. Francesco ha indicato 6 esperienze lavorative sul suo profilo. Simultaneous vs sequential combination of insulin glargine and lixisenatide in type 2 diabetes uncontrolled on metformin ePoster # 795 View ePoster. Francesco Giorgino sui naufragi nel Mediterraneo: ‘Il … Key efficacy and safety outcomes. Jiten Vora MD. Diabetes in the Time of COVID-19: A Twitter-Based Sentiment Analysis Show all authors.

Liquore Al Cioccolato Bimby, Ave Maria Testo Italiano, Crisafulli Quarto Oggiaro, Aldo Vitali, Giornalista Figlia, Ricordati Di Me Con Testo, Forni Da Incasso Misure Grandi, Frosinone Calcio Forum, Top Gun Mig 28,